ClinicalTrials.gg
RecruitingNCT06413654Updated May 5, 2026

A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)

A Phase 2/3 interventional study of B001 and Placebo in Neuromyelitis Optica Spectrum Disorders, sponsored by Shanghai Jiaolian Drug Research and Development Co., Ltd. Recruiting at 51 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Shanghai Jiaolian Drug Research and Development Co., Ltd · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 72 studies in Neuromyelitis Optica with a site in China — 37 open to participants now, 43 under way, 7 of them phase 3. Neuromyelitis Optica · China.

Planned enrollment
7th of 51
132 · median 23
Started
2024
with 10 others
Phase 2/3
3 of 72
1 open now
Primary completion
2027-10
later than 27 of 42 live
Registered
42nd of 72
by date

Among the 72 studies in Neuromyelitis Optica with a site in China, this one is the 7th largest by planned enrollment of the 51 interventional ones that give a count, is one of 11 that started in 2024, is one of 3 in phase 2/3, reaches primary completion later than 27 of the 42 other live ones, and was the 42nd registered.

Neuromyelitis Optica

178 studies on the registry are indexed under Neuromyelitis Optica; 78 are open to participants now.

Browse Neuromyelitis Optica studies →

Open to participants now

37 of the 72 studies in Neuromyelitis Optica with a site in China are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 50 Neuromyelitis Optica studies recruiting now, 29 (58%) set no upper age limit and 16 (32%) stop at 75 or younger; 11 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Neuromyelitis Optica with a site in China, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of B001 injection in aquaporin-4 antibody positive patients with neuromyelitis optica spectrum disorder.

03

Conditions studied

  • Neuromyelitis Optica Spectrum Disorders

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Confirmed NMOSD patients;
  2. Experienced at least 1 recurrence of NMOSD within 1 year or at least 2 recurrence within 2 years prior to screening;
  3. The blood pregnancy tests were negative within 7 days before the first dose in fertile female subjects. The fertile subjects and the male subjects whose partner are fertile woman agree to use reliable during the study period and within 6 months after the study drug discontinuation;
  4. Volunteer to participate in clinical research; Fully understand and know the study and sign the ; Willing to follow and able to complete all test procedures.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with severe NMOSD were judged by the researcher to be unfit to participate in this study;
  2. Subjects with chronic active immune system diseases undergoing systematic treatment;
  3. Received anti-CD20 or other cell depletion therapy within 6 months before first dose;
  4. Received the prescribed drug treatment at the prescribed time before first dose;
  5. Subjects who have participated in any drug clinical trials within 28 days prior to the first dose;
  6. Received hematopoietic stem cell transplantation、 lymphatic irradiation before first dose;
  7. Pregnant or lactating women; Subjects with birth plans during the trial;
  8. Subjects who had undergone major surgery within 2 months prior to screening or were scheduled to undergo major surgery during the trial;
  9. Subjects with severe, progressive, or uncontrolled disease who have been assessed by the investigator to be at increased risk of participating in the study;
  10. A history of gastrointestinal perforation and/or fistula within 6 months prior to screening;
  11. Subjects who received a live or attenuated vaccine within 4 weeks prior to initial administration, or who plan to receive vaccination during the study period;
  12. Subjects with severe or persistent infection currently or within the 1 months prior to screening;
  13. Subjects with positive gamma interferon release test;
  14. Subjects who currently have active hepatitis or have a history of severe liver disease;
  15. Uncontrolled systemic disease, or any other reason the investigator deems inappropriate for inclusion;
  16. Abnormal laboratory test results;
  17. Subjects with a history of alcohol or drug abuse in the 6 months prior to screeing, or who are abusing;
  18. Subjects with symptoms of severe mental illness who are clinically uncooperative;
  19. Subjects who were unable to undergo magnetic resonance imaging during the study and who had other conditions that the investigator considered inappropriate to enroll.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    B001 injection

    Drug: B001

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Time to first NMOSD Attack During RCP

    The NMOSD attack is defined as the presence of new or worsening symptom(s) related to NMOSD.

    Time frame: Approximately 48 weeks

Secondary outcomes

  1. Change in Expanded Disability Status Scale (EDSS) Score

    EDSS and its associated functional system (FS) score provide a system for quantifying disability and monitoring changes in the level of disability over time. EDSS consists of 7 FS (visual FS, brainstem FS, pyramidal FS, cerebellar FS, sensory FS, bowel and bladder FS, and cerebral FS) which are used to derive EDSS score ranging from 0 (normal neurological exam) to 10 (death from MS).

    Time frame: Approximately 48 weeks

  2. Change in Vision Acuity/ Low contrast visual acuity (VA/LCVA)

    Change in VA/LCVA

    Time frame: Approximately 48 weeks

  3. Annualized relapse rate (ARR)

    Annualized attack rate is defined as total number of attacks divided by total person years.

    Time frame: Approximately 3 years

  4. Change in Opticospinal Impairment Scale (OSIS)

    Change in OSIS

    Time frame: Approximately 48 weeks

  5. Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event is any AE that resulted in death, life threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.

    Time frame: Approximately 3 years

07

Study locations

51 of 51 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for Oct 2027, 39 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2024
First posted
May 14, 2024
StartActual
Jul 17, 2024
Primary completionEst.
Oct 31, 2027
CompletionEst.
Feb 28, 2029
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06413654
Lead sponsor
Shanghai Jiaolian Drug Research and Development Co., Ltd
Responsible party
Sponsor
First posted
May 14, 2024
Start date
Jul 17, 2024
Primary completion
Oct 31, 2027 (estimated)
Completion
Feb 28, 2029 (estimated)
Last update
May 5, 2026

Study contacts

FuDong Shi
Contact
ttyyirb@163.com
0086-010-59978555

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tambotatug · Anti-CD20 Monoclonal Antibody B001

Start the discussion